Inventor
MADIN ANDREW
GB54 patents
⚠️ This page may combine multiple inventors who share the name “MADIN ANDREW”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK SHARP & DOHME
23 patentsUS7144910B2Dec 5, 2006
Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors
MERCK SHARP & DOHME27 citations92
US6579875B1Jun 17, 2003
Triazolo-pyridazine derivatives as ligands for GABA receptors
MERCK SHARP & DOHME22 citations92
US6255305B1Jul 3, 2001
Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
MERCK SHARP & DOHME49 citations92
US6107321AAug 22, 2000
Diazabicyclooctane derivatives having selective 5-HT1Dalpha agonist activity
MERCK SHARP & DOHME21 citations92
US7138400B2Nov 21, 2006
Sulfamides as gamma-secretase inhibitors
MERCK SHARP & DOHME32 citations91
US5854268ADec 29, 1998
Azetidine, pyrrolidine and piperidine derivatives
MERCK SHARP & DOHME45 citations91
US6355798B1Mar 12, 2002
Triazolo-pyridazine derivatives as ligands for GABA receptors
MERCK SHARP & DOHME17 citations84
US7638629B2Dec 29, 2009
Piperidines and related compounds for treatment of alzheimer's disease
MERCK SHARP & DOHME13 citations83
US6828322B2Dec 7, 2004
Triazolo-pyridazine derivatives as ligands for GABA receptors
MERCK SHARP & DOHME14 citations83
US6140347AOct 31, 2000
Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists
MERCK SHARP & DOHME18 citations83
US7105509B2Sep 12, 2006
Benzodiazepine derivatives as APP modulators
MERCK SHARP & DOHME21 citations82
US6303605B1Oct 16, 2001
Triazolo-pyridazine derivatives as ligands for GABA receptors
MERCK SHARP & DOHME12 citations74
US7282513B2Oct 16, 2007
Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
MERCK SHARP & DOHME7 citations72
US7205434B2Apr 17, 2007
Sulphonamides for control of beta-amyloid production
MERCK SHARP & DOHME8 citations72
US7041689B2May 9, 2006
Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase
MERCK SHARP & DOHME7 citations72
US6630471B1Oct 7, 2003
Substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
MERCK SHARP & DOHME12 citations70
US6949549B2Sep 27, 2005
Imidazolophthalazine derivatives as ligands for GABAA receptors
MERCK SHARP & DOHME2 citations61
US7365196B2Apr 29, 2008
Sulphonamido-substituted bridged bicycloalkyl derivatives
MERCK SHARP & DOHME6 citations59
US5854247ADec 29, 1998
Piperazine, piperidine and tetrahydropyridine derivatives useful as 5-HT1 recepter agonists
MERCK SHARP & DOHME6 citations59
US7427621B2Sep 23, 2008
Cyclic sulfamides for inhibition of gamma-secretase
MERCK SHARP & DOHME0 citations51
US6051591AApr 18, 2000
Diazabicyclooctane derivatives
MERCK SHARP & DOHME0 citations42
US7514459B2Apr 7, 2009
Gamma-secretase inhibitors
MERCK SHARP & DOHME0 citations40
US7371771B2May 13, 2008
Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase
MERCK SHARP & DOHME0 citations40
MISSION THERAPEUTICS LTD
14 patentsUS9926307B2Mar 27, 2018
Compounds
MISSION THERAPEUTICS LTD14 citations92
US10392380B2Aug 27, 2019
Compounds
MISSION THERAPEUTICS LTD6 citations83
US11472798B2Oct 18, 2022
Compounds
MISSION THERAPEUTICS LTD1 citations72
US11130748B2Sep 28, 2021
Compounds
MISSION THERAPEUTICS LTD3 citations72
US10774078B2Sep 15, 2020
Compounds
MISSION THERAPEUTICS LTD2 citations72
US10640498B2May 5, 2020
Compounds
MISSION THERAPEUTICS LTD6 citations71
US11993595B2May 28, 2024
Compounds
MISSION THERAPEUTICS LTD0 citations62
US11958833B2Apr 16, 2024
Compounds
MISSION THERAPEUTICS LTD0 citations62
US10683269B2Jun 16, 2020
2-cyanoisoindoline derivatives for treating cancer
MISSION THERAPEUTICS LTD1 citations60
US11370784B2Jun 28, 2022
Cyano-substituted heterocycles with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11091488B2Aug 17, 2021
1-cyano-pyrrolidine derivatives as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11084821B2Aug 10, 2021
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11014912B2May 25, 2021
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11414402B2Aug 16, 2022
Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
MISSION THERAPEUTICS LTD0 citations50
GENENTECH INC
8 patentsUS11566003B2Jan 31, 2023
Isoquinolines as inhibitors of HPK1
GENENTECH INC4 citations72
US10407424B2Sep 10, 2019
Naphthyridines as inhibitors of HPK1
GENENTECH INC5 citations71
US11944606B2Apr 2, 2024
Azaindoles as inhibitors of HPK1
GENENTECH INC0 citations61
US10952995B2Mar 23, 2021
Azaindoles as inhibitors of HPK1
GENENTECH INC0 citations61
US11034692B1Jun 15, 2021
Naphthyridines as inhibitors of HPK1
GENENTECH INC1 citations60
US12297210B2May 13, 2025
Naphthyridine compounds and uses thereof
GENENTECH INC0 citations50
US12208088B2Jan 28, 2025
Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
GENENTECH INC0 citations50
US12378249B2Aug 5, 2025
Isoquinoline compounds and uses thereof
GENENTECH INC0 citations49
BERDINI VALERIO
3 patentsUS8895745B2Nov 25, 2014
Bicyclic heterocyclic compounds as FGFR inhibitors
BERDINI VALERIO33 citations92
US8513276B2Aug 20, 2013
Imidazo[1,2-a]pyridine compounds for use in treating cancer
BERDINI VALERIO8 citations82
US8796244B2Aug 5, 2014
Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
BERDINI VALERIO2 citations50
SAXTY GORDON
1 patentDIMOPOULOS PASCHALIS
1 patentShowing the top 50 of 54 patents by PatentIndex Score.